Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.97)
# 3,736
Out of 4,886 analysts
122
Total ratings
28.69%
Success rate
-24.78%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.06 | +654.72% | 4 | Jun 27, 2025 | |
| ARDX Ardelyx | Assumes: Buy | $10 | $4.48 | +123.21% | 1 | Jun 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $13.95 | +201.08% | 9 | Jun 17, 2025 | |
| LYRA Lyra Therapeutics | Maintains: Neutral | $2 → $16 | $9.25 | +72.97% | 8 | Jun 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $20 | $9.02 | +121.73% | 10 | Jun 9, 2025 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $8 | $3.71 | +115.63% | 1 | Jun 4, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $10 | $3.65 | +173.97% | 5 | May 29, 2025 | |
| UBX Unity Biotechnology | Downgrades: Neutral | $4 → $2 | $0.20 | +899.50% | 9 | May 27, 2025 | |
| TARS Tarsus Pharmaceuticals | Assumes: Buy | $72 | $39.68 | +81.45% | 1 | May 27, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $4.33 | +131.21% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $9.93 | +202.11% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.40 | +1,150.00% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.29 | +286.01% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $31.32 | +21.33% | 5 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.83 | +1,105.98% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.61 | +1,882.49% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $2.04 | -1.96% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $3.88 | -22.68% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $4.22 | +753.08% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $286.36 | -90.22% | 1 | Aug 22, 2023 |
Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.06
Upside: +654.72%
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $4.48
Upside: +123.21%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $13.95
Upside: +201.08%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2 → $16
Current: $9.25
Upside: +72.97%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $9.02
Upside: +121.73%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.71
Upside: +115.63%
DiaMedica Therapeutics
May 29, 2025
Reiterates: Buy
Price Target: $10
Current: $3.65
Upside: +173.97%
Unity Biotechnology
May 27, 2025
Downgrades: Neutral
Price Target: $4 → $2
Current: $0.20
Upside: +899.50%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $39.68
Upside: +81.45%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.33
Upside: +131.21%
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $9.93
Upside: +202.11%
May 15, 2025
Reiterates: Buy
Price Target: $30
Current: $2.40
Upside: +1,150.00%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $8.29
Upside: +286.01%
May 8, 2025
Reiterates: Buy
Price Target: $38
Current: $31.32
Upside: +21.33%
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $0.83
Upside: +1,105.98%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.61
Upside: +1,882.49%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $2.04
Upside: -1.96%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $3.88
Upside: -22.68%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $4.22
Upside: +753.08%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $286.36
Upside: -90.22%